The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients.

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration ...

The push to bring a subcutaneous version of Keytruda to market comes as Merck prepares for loss of exclusivity. (Photo by Kena Betancur/Getty Images) Merck has talked up the value of its subcutaneous ...

Since 2015, NHS patients have received the world's best-selling drug through a drip – or intravenous infusion – which can take more than an hour to administer in hospital. NHS England says the new ...

Because Keytruda is an intravenous infusion and not a medicine that a person can self-administer, Medicare Part B will help pay for the drug. Part B covers medical services, including doctor’s visits, ...

Health minister hopes a key injectable cancer drug will be available in all five trusts "as soon as possible".

The U.S. Food and Drug Administration (FDA) has approved a new way to give pembrolizumab (brand name: Keytruda), one of the most widely used immunotherapy treatments for cancer. For the first time, ...

Both Opdivo and Keytruda come as liquid solutions. The two drugs are given as an intravenous (IV) infusion, which is an injection into your vein given over a period of time. Infusions for both Opdivo ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Merck & Co., Inc. is placed fourth among them. Merck & Co., Inc. (NYSE:MRK), a global ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut ...